Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Summit Therapeutics Inc — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $118.73, while Summit Therapeutics Inc trades at $17.55 (market cap $13.79B). The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| QQQE | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $26.38 |
52-Week Low | $96.06 | $12.43 |
Market Cap | — | $13.79B |
Enterprise Value | — | $13.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE trades at $119.78, down 0.8% on the day, with a neutral technical signal overall. The ETF provides equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights the potential inclusion of SpaceX in the underlying index, which could drive new investor interest. Technical indicators show mixed signals with bullish moving averages but neutral oscillators.
The outlook for QQQE remains tied to Nasdaq-100 performance, with equal weighting offering defensive characteristics during market rotations. Key risks include tech sector volatility and index composition changes. The ETF's structure provides diversification benefits for investors seeking Nasdaq exposure without heavy concentration in mega-cap tech names.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
